SARS-CoV Spike antibody (N-Term)

Catalog No. ABIN7794779

This Mouse Monoclonal antibody specifically detects SARS-CoV Spike in Neut. It exhibits reactivity toward SARS Coronavirus (SARS-CoV).

Quick Overview for SARS-CoV Spike antibody (N-Term) (ABIN7794779)

Target: SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Reactivity: SARS Coronavirus (SARS-CoV)

Host: Mouse

Clonality: Monoclonal

Conjugate: This SARS-CoV Spike antibody is un-conjugated

Application: Neutralization (Neut)

Clone: COV1-65

Product Details anti-SARS-CoV Spike Antibody

Binding Specificity: N-Term

Purpose: Anti-SARS-CoV-1, Spike NTD (Clone COV1-65)-Purified No Carrier Protein

Specificity: COV1-65 targets the N-terminal domain (NTD) of the SARS-CoV-1 prefusion spike protein, distributed on the viral surface. Antigen Distribution Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. COV1-65 is a monoclonal antibody specific to the N-terminal domain (NTD) of the SARS-CoV-1 spike protein. Unlike antibodies targeting the RBD, COV1-65 does not block the ACE2 receptor but does function as a neutralizer. The NTD is important for the virus's structural integrity and function, and targeting this domain could disrupt the viral life cycle in other ways. COV1-65's binding to the NTD suggests it could be useful in inhibiting viral attachment or fusion indirectly or in combination with other neutralizing antibodies, providing a broader approach to preventing infection.

Purification: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Purity: >=90 % monomer by analytical SEC and SDS-Page

Isotype: IgG1 lambda

Application Details

Restrictions: For Research Use only

Handling

Concentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Preservative: Without preservative

Storage: 4 °C,-80 °C

Storage Comment: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Target Details for SARS-CoV Spike

Target: SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Alternative Name: SARS-CoV Spike

Target Type: Viral Protein